Attached files
| file | filename |
|---|---|
| EX-9.01A - ASAMBLEA GENERAL ORDINARIA DE ACCIONISTAS - GENETHERA INC | meeting_ex9z01a.htm |
| EX-9.01B - APPLIED GENETICS APPOINTS DR - GENETHERA INC | appoint_ex9z01b.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2012
GENETHERA, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-27237 | 65-0622463 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
7577 W. 103rd Ave. Suite 212, Westminster, CO | 80021 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 439-2085
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions. |
|
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02 APPOINTMENT OF CERTAIN OFFICERS
On November 29, 2011, the Shareholders of Applied Genetics met in Monterrey, Mexico and unanimously approved the Appointment of Dr. Antonio (Tony) Milici, Chief Executive Officer and Chairman of the Board of GeneThera Inc. (the “Registrant’), as the new Interim President of Applied Genetics.
Item 9.01 EXHIBITS
Exhibit Number
Description
1 Shareholders Meeting and Resolution to Appoint Dr. Tony Milici as
President of Applied Genetics; and
2 Press Release dated January 10, 2012 announcing Dr. Milici’s
Appointment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
GeneThera, Inc.
a Nevada Corporation
By:/s/ Antonio Milici
Antonio Milici, Chief Executive Officer
Date: January 10, 2012